A novel angiogenic peptide named AG30 (angiogenic peptide 30) was discovered in exploratory research at Osaka University1), 2). AG30 consists of 30 amino acids and has the unique pharmacological effects of angiogenesis and antimicrobial functions. Using AG30 as a basis and repeatedly modifying it to replace some of its amino acids, SR-0379 was created to exhibit those same pharmacological effects3). In addition, adjuvant-like peptide "AJP001"4) and antimicrobial peptide "Curepeptin" have been created after partial modification of amino acid sequences in AG30.
1) Nishikawa T, Nakagami H, Maeda A, et al: Development of a novel antimicrobial peptide, AG-30, with angiogenic properties. J Cell Mol Med. 2009: 13; 535-546
2) Nakagami H, Nishikawa T, Tamura N, Maeda A, Hibino H, Mochizuki M, Shimosato T, Moriya T, Morishita R, Tamai K, Tomono K, Kaneda Y. Modification of a Novel Angiogenic Peptide, AG30, for the Development of Novel Therapeutic Agents. J Cell Mel Med 2012 Jul;16(7):1629-1639
3) Tomioka H, Nakagami H, Tenma A, Saito Y, Kaga T, Kanamori T, Tamura N, Tomono K, Kaneda Y, Morishita R. Novel anti-microbial peptide SR-0379 accelerates wound healing via the PI3 kinase/akt/mTOR pathway. PLoS One 2014;9:e92597.
4) Tenma A，Nakagami H，Tomioka H，Sakaguchi M，Ide R，Koriyama H，Hayashi H，Shimamura M， Rakugi H，Morishita.，AJP001, a novel helper T-cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine. FASEB Bioadv. 2019 Nov 22;1(12):760-772.